Sexual Dysfunction in Women with Cancer: A Systematic Review of Longitudinal Studies

Guedes, Thais Sousa Rodrigues; Guedes, Marcello Barbosa Otoni Gonçalves; Santana, Rebeca de Castro; Silva, José Felipe Costa da; Dantas, Amanda Almeida Gomes; Ochandorena-Acha, Mirari; Terradas-Monllor, Marc; Jerez-Roig, Javier; Souza, Dyego Leandro Bezerra de

doi:10.3390/ijerph191911921

Cited by 25 publications

(22 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the exposed group had a worse sexual function in all domains assessed by the Female Sexual Function Index. Our ndings corroborate previous studies and highlight the importance of periodically assessing the sexual function of women diagnosed with breast cancer and under treatment [22][23][24] .…”

Section: Discussionsupporting

confidence: 91%

“…Furthermore, regardless of the category of dysfunction, women had a 2.7 to 3.5 times greater risk of developing sexual dysfunction. Cervical, breast, and endometrial cancers were the most frequently associated with sexual dysfunction 22 . However, the anatomical location of the tumor is not the only cause of sexual dysfunction in women with cancer as it might also be induced by physiological changes from side effects of cancer treatments 22 .…”

Section: Discussionmentioning

confidence: 99%

“…A recent systematic review showed an incidence of 30-80% of sexual dysfunction in women with cervical, gynecological, and breast cancer 22 . Furthermore, regardless of the category of dysfunction, women had a 2.7 to 3.5 times greater risk of developing sexual dysfunction.…”

Section: Discussionmentioning

confidence: 99%

“…However, the anatomical location of the tumor is not the only cause of sexual dysfunction in women with cancer as it might also be induced by physiological changes from side effects of cancer treatments 22 . Reports of gynecological problems including decreased vaginal lubrication, sexual desire and arousal, and di culty or inability to reach orgasm can result in sexual dysfunction 22,23 .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Sexual dysfunction in women with breast cancer: a retrospective longitudinal study

Guedes,

Lopes

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background Breast cancer treatment leads to physical and psychological changes. The aim of this study is to analyze the incidence of sexual dysfunction and its risk factors in women diagnosed with breast cancer. Methods This retrospective cohort study included women diagnosed and treated for breast cancer (exposed group, n = 90) and healthy women (non-exposed group, n = 93). Data were collected from medical records and using the Female Sexual Function Index (FSFI) questionnaire. Primary outcomes were analyzed using binary logistic regression. The Mann-Whitney test was used to analyze FSFI domains between groups. Results The exposed group had a 74% incidence of sexual dysfunction and 3.9 times increased chances of having sexual dysfunction compared with the non-exposed group (OR: 3.9, CI: 1.8 to 8.2, p < 0.001). Presence of comorbidities increased the chances of sexual dysfunction by 2.5 times (OR: 2.5, CI: 1.2 to 4.9, p = 0.009). Conclusion Women diagnosed and treated for breast cancer had a higher incidence of sexual dysfunction than healthy women. Furthermore, comorbidities also increased the chances of sexual dysfunction regardless of exposure to breast cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Sexual dysfunction in women with breast cancer: a retrospective longitudinal study

Guedes,

Lopes

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Sexual health is an important aspect of HRQoL [21, 22], and sexual problems have a high prevalence of in cancer survivors [23]. Despite this fact, the only normative EORTC data on sexual health are from a Dutch normative study incorporating five sexual single items from the EORTC’s item bank [24].…”

Section: Introductionmentioning

confidence: 99%

Norwegian general population normative data for the EORTC questionnaires; the core QLQ-C30, the sexual health questionnaire QLQ-SHQ22, and sexual domains of the QLQ-BR23/BR45

Åsberg¹,

Nilsen

Hjermstad

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective: The aim of this study was to provide gender, age, and morbidity specific Norwegian general population normative values for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires QLQ C30, the sexual health questionnaire QLQ SHQ22, and the sexual domains of the breast modules QLQ BR23 and QLQ BR45. Methods: A random nation-wide sample stratified by gender and age groups (18 to 29, 30 to 39, 40 to 49, 50 to 59, 60 to 69 and 70 to 79 years) was drawn from the Norwegian National Population Register. Participants were notified through National online health services (HelseNorge) and by postal mail. The survey included sociodemographic background information, HRQoL assessed by the EORTC questionnaires, and morbidity by The Self Administered Comorbidity Questionnaire. Multivariable linear regression was carried out to estimate the associations of age, sex, and morbidity with the EORTC scale and item scores. Results: Of the 15,627 eligible individuals, 5.135 (33%) responded. Women and persons with morbidities reported lower functioning and higher symptom burden than men and persons without morbidities, respectively, on nearly all EORTC scales. Sex differences were most prominent for Emotional Functioning, Pain, Fatigue, and Insomnia (QLQ C30), Body Image, Sexual Functioning (QLQ BR23/45), Importance of Sexual Activity, Libido, and Fatigue (QLQ SHQ22). The score differences between persons with and without morbidity were highly significant and largest among the youngest and middle-aged groups. Conclusion: The present study is the first to provide normative values for the EORTC sexual health questionnaire QLQ SHQ22 and the sexual subscales of the QLQ BR23 and QLQ BR45, for all separately in age groups by sex and morbidity.

show abstract

Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review

Güven,

Thong,

Arndt

2024

J Cancer Surviv

View full text Add to dashboard Cite

Background Immune checkpoint inhibitors (ICIs) have become a central part of cancer care. However, the survivorship outcomes in patients treated with ICIs are understudied. Therefore, we conducted a scoping review to evaluate the current status of the field and to establish research gaps regarding survivorship outcomes with ICIs in real-life cohorts. Methods We used the Web of Science, PubMed, and Embase databases to systematically filter published studies with real-life cohorts from January 1, 2010, until October 19, 2022. Studies evaluating at least one survivorship outcome in ICI-treated patients were included. Results A total of 39 papers were included. Quality of life (QoL) (n = 23), toxicity burden (n = 16), and psychosocial issues (n = 9) were the most frequently evaluated survivorship outcomes. Anti-PD-1/PD-L1 monotherapy and a response to treatment were associated with better QoL. In addition, the ICIs were associated with grade 3 or higher immune-related adverse events (irAEs) in 10–15% and late/long-term irAEs in 20–30% of the survivors. Regarding psychosocial problems, over 30% of survivors showed evidence of anxiety and depression, and 30–40% of survivors reported neurocognitive impairments. Conclusion The survivors treated with ICIs have impairments in most survivorship domains. Further research is needed to gather data on the understudied survivorship outcomes like late and long-term effects, fertility, financial toxicity, and return to work in survivors treated with ICIs. Implications for Cancer Survivors Available evidence demonstrates that a significant portion of survivors treated with ICIs have a significant toxicity burden, lower QoL than the general population, and a high rate of psychosocial problems.

show abstract

Sexual Dysfunction in Women with Cancer: A Systematic Review of Longitudinal Studies

Cited by 25 publications

References 54 publications

Sexual dysfunction in women with breast cancer: a retrospective longitudinal study

Sexual dysfunction in women with breast cancer: a retrospective longitudinal study

Norwegian general population normative data for the EORTC questionnaires; the core QLQ-C30, the sexual health questionnaire QLQ-SHQ22, and sexual domains of the QLQ-BR23/BR45

Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review

Contact Info

Product

Resources

About